Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

NCT01355393 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer
Male Breast Cancer
Recurrent Breast Cancer
Stage II Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer

Interventions

BIOLOGICAL: HER-2/neu peptide vaccine
BIOLOGICAL: sargramostim
DRUG: rintatolimod

Sponsor

University of Washington

Collaborators

[object Object]